10 Best Value Stocks to Buy According to Billionaires

4. Gilead Sciences, Inc. (NASDAQ:GILD)

Forward P/E as of June 30: ~14.0x

Number of Hedge Fund Holders: 79

Dollar Value of Billionaire Holdings: $1.65 billion

Number of Billionaire Investors: 14

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo® (lenacapavir), Gilead Sciences, Inc. (NASDAQ:GILD)’s injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in order to reduce the risk of sexually acquired HIV in adults and adolescents weighing a minimum of 35 kg. The company’s Chief Executive added that this medicine is required to be given twice a year, and it has demonstrated strong outcomes in clinical studies, meaning it can transform HIV prevention.

The approval of Gilead Sciences, Inc. (NASDAQ:GILD)’s New Drug Applications (NDAs) for Yeztugo was supported by data from Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by the company. In the US, Gilead Sciences, Inc. (NASDAQ:GILD) continues to work closely with insurers, healthcare systems, and other payers, targeting to ensure broad insurance coverage for Yeztugo. Furthermore, for eligible commercially insured individuals with commercial insurance, the company’s Advancing Access® Co-Pay Savings Program is expected to reduce out-of-pocket costs to as low as zero dollars.

Notably, HIV product sales saw an increase of 6% to $4.6 billion in Q1 2025 as compared to the same period in 2024. This was mainly driven by increased average realized price and demand. Impax Asset Management, an investment management company, released its Q1 2025 investor letter. Here is what the fund said:

“Gilead Sciences, Inc. (NASDAQ:GILD) (Health Care) the company is owned due to its role in solving evolving heath care challenges through the development of new medical treatments for conditions as chronic diseases are on the rise. The company also has one of the highest systematic ESG scores in the portfolio. Gilead reported better-than-expected quarterly results, largely driven by strong revenue from its HIV franchise. The company also provided an optimistic earnings guidance for the next fiscal year, helping provide defensiveness amid a flurry of volatility.”